Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
In the latest session, Vir Biotechnology Inc (NASDAQ: VIR) closed at $5.41 down -1.46% from its previous closing price of $5.49. In other words, the price has decreased by -$1.46 from its previous closing price. On the day, 2.07 million shares were traded. VIR stock price reached its highest trading level at $5.6166 during the session, while it also had its lowest trading level at $5.305.
Ratios:
For a deeper understanding of Vir Biotechnology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.79 and its Current Ratio is at 6.79. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 15 ’25 when Eisner Mark sold 6,796 shares for $5.47 per share. The transaction valued at 37,162 led to the insider holds 108,204 shares of the business.
Eisner Mark sold 3,586 shares of VIR for $19,629 on Jul 17 ’25. The EVP and Chief Medical Officer now owns 104,618 shares after completing the transaction at $5.47 per share. On Jul 17 ’25, another insider, MARK EISNER, who serves as the Officer of the company, bought 3,586 shares for $5.41 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 747867584 and an Enterprise Value of -8847465. For the stock, the TTM Price-to-Sale (P/S) ratio is 35.85 while its Price-to-Book (P/B) ratio in mrq is 0.72. Its current Enterprise Value per Revenue stands at -0.424 whereas that against EBITDA is 0.016.
Stock Price History:
The Beta on a monthly basis for VIR is 1.19, which has changed by -0.46699506 over the last 52 weeks, in comparison to a change of 0.13161862 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.32. The 50-Day Moving Average of the stock is 4.86%, while the 200-Day Moving Average is calculated to be -25.34%.
Shares Statistics:
For the past three months, VIR has traded an average of 1.31M shares per day and 1440980 over the past ten days. A total of 138.06M shares are outstanding, with a floating share count of 89.12M. Insiders hold about 35.54% of the company’s shares, while institutions hold 53.76% stake in the company. Shares short for VIR as of 1749772800 were 11367540 with a Short Ratio of 8.57, compared to 1747267200 on 10942673. Therefore, it implies a Short% of Shares Outstanding of 11367540 and a Short% of Float of 13.29.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The performance of Vir Biotechnology Inc (VIR) in the stock market is under the watchful eye of 7.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is -$0.74, with high estimates of -$0.54 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$2.48 and -$4.07 for the fiscal current year, implying an average EPS of -$3.19. EPS for the following year is -$3.08, with 8.0 analysts recommending between -$2.23 and -$4.23.
Revenue Estimates
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $68M, while the lowest revenue estimate was $3M, resulting in an average revenue estimate of $16.91M. In the same quarter a year ago, actual revenue was $74.2MBased on 8 analysts’ estimates, the company’s revenue will be $16.48M in the next fiscal year. The high estimate is $53M and the low estimate is $3M.
